ImageneBio financials
$4.58−1.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$11.8M | -$12.1M | -$8.5M | -$26.6M |
| Net income | -$10.2M | -$10.6M | -$6.9M | -$25.6M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.63 | $-0.95 | $-1.18 | $-2.91 |
| EBITDA | -$11.8M | -$12.1M | -$8.1M | -$26.8M |
| Operating cash flow | -$9.1M | -$14.8M | -$7.2M | -$26.6M |
| Free cash flow | -$9.1M | -$14.8M | -$7.2M | -$26.6M |
| Diluted shares | 16.2M | 11.2M | 5.9M | 8.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $94.7M | $76.0M | $94.5M | $103.2M |
| Short-term investments | $41.5M | $41.2M | $40.8M | $39.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $152.0M | $136.7M | $153.0M | $160.9M |
| Total liabilities | $10.0M | $13.4M | $19.8M | $21.0M |
| Shareholders' equity | $142.1M | $123.3M | $133.1M | $139.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology